NASDAQ:HZNP Horizon Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Horizon Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $79.93 +1.97 (+2.53 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$78.14Now: $79.93▼$81.1850-Day Range$58.90MA: $71.31▼$78.9752-Week Range$23.81Now: $79.93▼$81.18Volume4.14 million shsAverage Volume2.23 million shsMarket Capitalization$16.50 billionP/E Ratio32.76Dividend YieldN/ABeta1.22 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingHorizon Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $77.31, Horizon Therapeutics has a forecasted downside of 3.3% from its current price of $79.93.Amount of Analyst CoverageHorizon Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.3 Community Rank Outperform VotesHorizon Therapeutics has received 848 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHorizon Therapeutics has received 426 “underperform” votes. (Add your “underperform” vote.)Community SentimentHorizon Therapeutics has received 66.56% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote “Outperform” if you believe HZNP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHorizon Therapeutics does not currently pay a dividend.Dividend GrowthHorizon Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Horizon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,042,766.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Horizon Therapeutics is held by insiders.Percentage Held by Institutions89.17% of the stock of Horizon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Horizon Therapeutics are expected to grow by 64.62% in the coming year, from $2.60 to $4.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Horizon Therapeutics is 32.76, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.83.Price to Earnings Ratio vs. SectorThe P/E ratio of Horizon Therapeutics is 32.76, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.49.Price to Earnings Growth RatioHorizon Therapeutics has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHorizon Therapeutics has a P/B Ratio of 6.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 3.1 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.98 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP Previous Symbol CUSIP44047T10 CIK1492426 Webwww.horizontherapeutics.com Phone011-353-1772-2100Debt Debt-to-Equity Ratio0.42 Current Ratio1.51 Quick Ratio1.45Price-To-Earnings Trailing P/E Ratio32.76 Forward P/E Ratio30.74 P/E Growth0.94 Sales & Book Value Annual Sales$1.30 billion Price / Sales12.69 Cash Flow$3.93 per share Price / Cash Flow20.33 Book Value$11.67 per share Price / Book6.85Profitability EPS (Most Recent Fiscal Year)$1.94 Net Income$573.02 million Net Margins34.09% Return on Equity19.67% Return on Assets9.59%Miscellaneous Employees1,200 Outstanding Shares206,460,000Market Cap$16.50 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $79.93 +1.97 (+2.53 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive HZNP News and Ratings via Email Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter. Horizon Therapeutics (NASDAQ:HZNP) Frequently Asked Questions How has Horizon Therapeutics' stock price been impacted by Coronavirus (COVID-19)? Horizon Therapeutics' stock was trading at $30.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HZNP shares have increased by 162.0% and is now trading at $79.93. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Horizon Therapeutics? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Horizon Therapeutics. When is Horizon Therapeutics' next earnings date? Horizon Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Horizon Therapeutics. How were Horizon Therapeutics' earnings last quarter? Horizon Therapeutics PLC (NASDAQ:HZNP) released its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.36 by $0.04. The biopharmaceutical company had revenue of $462.80 million for the quarter, compared to the consensus estimate of $333.70 million. Horizon Therapeutics had a net margin of 34.09% and a return on equity of 19.67%. Horizon Therapeutics's quarterly revenue was up 44.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.49 earnings per share. View Horizon Therapeutics' earnings history. What guidance has Horizon Therapeutics issued on next quarter's earnings? Horizon Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, August, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.85-1.9 billion, compared to the consensus revenue estimate of $1.54 billion. What price target have analysts set for HZNP? 12 equities research analysts have issued 12 month price targets for Horizon Therapeutics' shares. Their forecasts range from $35.00 to $112.00. On average, they expect Horizon Therapeutics' stock price to reach $77.31 in the next twelve months. This suggests that the stock has a possible downside of 3.3%. View analysts' price targets for Horizon Therapeutics. Are investors shorting Horizon Therapeutics? Horizon Therapeutics saw a decline in short interest in July. As of July 31st, there was short interest totaling 4,790,000 shares, a decline of 27.3% from the July 15th total of 6,590,000 shares. Based on an average trading volume of 2,750,000 shares, the short-interest ratio is currently 1.7 days. View Horizon Therapeutics' Short Interest. Who are some of Horizon Therapeutics' key competitors? Some companies that are related to Horizon Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors. What other stocks do shareholders of Horizon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics investors own include Alibaba Group (BABA), Opko Health (OPK), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), AbbVie (ABBV), Tesla (TSLA), Micron Technology (MU) and TherapeuticsMD (TXMD). Who are Horizon Therapeutics' key executives? Horizon Therapeutics' management team includes the following people: Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)Dr. Shao-Lee Lin M.D., Ph.D., Exec. VP, Head of R&D and Chief Scientific Officer (Age 52)Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)Mr. Robert F. Carey, Exec. VP & Chief Bus. Officer (Age 60) What is Horizon Therapeutics' stock symbol? Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HZNP." Who are Horizon Therapeutics' major shareholders? Horizon Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.60%), William Blair Investment Management LLC (3.69%), FMR LLC (3.53%), Paulson & CO. Inc. (3.34%), Orbimed Advisors LLC (1.39%) and Nuveen Asset Management LLC (1.27%). Company insiders that own Horizon Therapeutics stock include Barry Moze, Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani. View institutional ownership trends for Horizon Therapeutics. Which major investors are selling Horizon Therapeutics stock? HZNP stock was sold by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Paulson & CO. Inc., Jennison Associates LLC, Glenmede Trust Co. NA, William Blair Investment Management LLC, Viking Global Investors LP, Bank of Montreal Can, and First Trust Advisors LP. Company insiders that have sold Horizon Therapeutics company stock in the last year include Barry Moze, Brian K Beeler, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, and Vikram Karnani. View insider buying and selling activity for Horizon Therapeutics. Which major investors are buying Horizon Therapeutics stock? HZNP stock was acquired by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, FMR LLC, Frontier Capital Management Co. LLC, Goldman Sachs Group Inc., Summit Partners Public Asset Management LLC, Scout Investments Inc., Orbimed Advisors LLC, and Nuveen Asset Management LLC. View insider buying and selling activity for Horizon Therapeutics. How do I buy shares of Horizon Therapeutics? Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Horizon Therapeutics' stock price today? One share of HZNP stock can currently be purchased for approximately $79.93. How big of a company is Horizon Therapeutics? Horizon Therapeutics has a market capitalization of $16.50 billion and generates $1.30 billion in revenue each year. The biopharmaceutical company earns $573.02 million in net income (profit) each year or $1.94 on an earnings per share basis. Horizon Therapeutics employs 1,200 workers across the globe. What is Horizon Therapeutics' official website? The official website for Horizon Therapeutics is www.horizontherapeutics.com. How can I contact Horizon Therapeutics? Horizon Therapeutics' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
